^
    Back
    Association details:
    Biomarker:FLT3-ITD mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:Max-40279 (PDGFR inhibitor, FLT3 inhibitor, FGFR1 inhibitor, FGFR2 inhibitor, JAK inhibitor, HPK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2018
    Title:

    Preclinical Evaluation of MAX-40279, a FLT3/FGFR Dual Kinase Inhibitor for Treatment of Acute Myeloid Leukemia

    Published date:
    11/01/2018
    Excerpt:
    MAX-40279 demonstrated superior FGFR inhibitory activity and higher bone marrow drug concentration while maintaining similar activity against FLT3-ITD.
    DOI:
    https://doi.org/10.1182/blood-2018-99-110414